Changchun Ruizhou Biopharmaceutical

Changchun Ruizhou Biopharmaceutical is a clinical-stage biotechnology company headquartered in Changchun, China, dedicated to the research, development, and commercialization of recombinant protein vaccines. The company's primary focus is on addressing infectious diseases with high clinical demand, particularly through its advanced pipeline of Human Papillomavirus (HPV) vaccines. Its lead candidate is a 9-valent HPV vaccine currently in late-stage clinical trials, alongside an innovative 11-valent candidate designed for broader coverage. Beyond HPV, Ruizhou is advancing recombinant vaccines for Herpes Zoster (Shingles) and Respiratory Syncytial Virus (RSV). The company utilizes a proprietary recombinant protein expression platform to ensure high purity and scalability of its vaccine antigens. By integrating R&D with large-scale manufacturing capabilities, Changchun Ruizhou Biopharmaceutical aims to become a leading provider of affordable and effective preventive biologics.